Atopic dermatitis treatment escalation is hindered by payer rules and inadequate tracking, according to experts at a recent roundtable. They highlighted issues like step therapy requirements and billing-focused documentation, which slow down appropriate care. These barriers were discussed at The American Journal of Managed Care®’s Population Health Roundtable in San Francisco, California, where participants also identified pharmacy teams, patient-reported outcome tools, and simple dashboards as near-term solutions.
Challenges in Capturing Disease Burden
Participants noted that body surface area is recorded primarily for billing, not to assess patient well-being. Validated patient-reported scores are rarely integrated into visits, making it difficult to identify underreported suffering. Additionally, patients with skin of color often face a high disease burden but are graded lower on severity scales, further complicating accurate assessment. Socioeconomic barriers, such as limited access to care, are also underdocumented compared to body surface area, despite their significant impact on treatment outcomes.
Undertreatment was flagged among young adults, patients with skin of color, and middle-aged to older Asian patients. Pediatric families face long waits for dermatology and allergy appointments.
Therapy Decisions and Pathway Gaps
Several participants said their health systems had no defined atopic dermatitis pathway, so escalation varies by clinician, and referrals arrive unpredictably, often from patients who have tried little and waited 6 months. Topical therapy is underused in children due to parental concerns about steroids. One participant estimated that over half of young patients receive no prior treatment. The lack of defined pathways was partly attributed to the gap between dermatologist availability and patient demand, making it challenging to implement standardized care protocols.
Read Also: Short US residence tied to less screening
While guidelines aid treatment choices, insurance approvals remain the ultimate determinant. Medicare was cited as the toughest barrier, often leaving patients without assistance. Responses to denials vary, with some clinicians appealing and others switching to covered drugs. One participant noted that denials often seem automated, making appeals a viable option, while another prefers to avoid the process altogether.
Escalation is increasingly driven by patients, who often raise concerns about long-term safety after online research. Managing expectations, such as explaining that itch relief precedes rash improvement, is key. Patients and parents frequently bring up safety worries influenced by news coverage of lawsuits, requiring clinicians to address these anxieties during consultations.
Role of Pharmacy Teams and Follow-Up Solutions
In-house specialty pharmacies were praised for handling prior authorizations and managing refills. However, visibility is lost when prescriptions move to outside mail-order pharmacies, leading to lapses in care. Some participants have started discharging stable patients to primary care for annual refills, freeing up appointments for those in greater need.
To improve long-term follow-up, participants suggested dashboards tracking patients by biologic and visit history, automated patient-reported outcomes, and alerts for covered biologics. A shared clinic model for immune-mediated inflammatory diseases was also proposed. One clinician highlighted the challenge of not knowing which patients are on specific biologics, such as Dupixent, showing the need for better tracking systems.
